Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India

Clinical Infectious Diseases

Volumn 48, Issue 4, 2009, Pages 400-406

  Kumar, Rashmi ^a   Tripathi, Piyush ^a   Baranwal, Madan ^a   Singh, Sudhakar ^a   Tripathi, Sanjeev ^a   Banerjee, Gopa ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN M ANTIBODY; RIBAVIRIN;

ANEMIA; ARTICLE; CHILD; CHILD HOSPITALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC ENCEPHALITIS; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HEPATOMEGALY; HOSPITAL DISCHARGE; HUMAN; INDIA; INFANT; JAPANESE ENCEPHALITIS VIRUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SIDE EFFECT; SPLENOMEGALY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; ENCEPHALITIS, JAPANESE; HUMANS; INDIA; INFANT; LENGTH OF STAY; PLACEBOS; RIBAVIRIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 58749115381     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/596309     Document Type: Article

References (38)

1. World Health Organization. Japanese encephalitis. 2008. Available at: http://www.who.int/biologicals/areas/vaccines/jap-encephalitis/en/index. html. Accessed 13 December 2007.
2. Kumar R. Viral encephalitis of public health significance in India. Indian J Pediatr 1999; 66:73-84.
3. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomized double-blind placebo-controlled trial. Lancet 2003; 361:821-6.
4. Gould EA, Solomon T, Mackenzie JS. Does antiviral therapy have a role in the control of Japanese encephalitis? Antiviral Res 2008; 78:140-9.
5. Prusoff WH, Krenitsky TA, Barry DW. Antiviral drugs. In: Munson E, ed. Principles of pharmacology. New York: Chapman & Hall, 1995: 1425-6.
6. Hirsch MS, Kaplan JC, D'Aquila RT. Antiviral agents In: Field BN, Knipe DM, Howley PN, eds. Field's virology. 3rd ed. Philadelphia: Lippincott, Williams & Wilkins, 1996:454-6.
7. Ribavirin. Available at: http://aidsinfo.nih.gov/drugsNew/DrugDetail T.aspx?int-id=28. Accessed 12 February 2007.
8. Crance JM, Scaramozzino N, Jouan A, Garin D. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. Antiviral Res 2003; 58:73-9.
9. Huggins JW, Robins RK, Canonico PG. Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses and arenaviruses. Antimicrob Agents Chemother 1984; 26:476-80.
10. Lung CC, Liu Chiu, Chiang H-Y. Inhibition of Japanese encephalitis virus replication in BHK-21 cells by ribavirin. In: Program and abstracts of the 11th International Congress of Virology (Sydney, Australia). 1999.
11. Jordan I, Briese T, Fischer N, Lau JYN, Lipkin WI. Ribavirin inhibits West Nile virus replication and cytopathic effect in neural cells. J Infect Dis 2000; 182:1214-7.
12. Leyssen P, Drosten C, Paning M, et al. Interferons, interferon inducers and interferon ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 2003; 47:777-82.
13. Huggins JW, Kim GK, Brand OM, McKee KT Jr. Ribavirin therapy for Hantavirus infection in suckling mice. J Infect Dis 1986; 153:489-97.
14. Neyts J, Meerbach A, McKenna P, De Clercq E. Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infection. Antiviral Res 1996; 30:125-32.
15. Mc Cormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986; 314:20-6.
16. Enria D, Maiztegni JI. Antiviral treatment of Argentinian hemorrhagic fever. Antiviral Res 1994; 23:23-31.
17. Huggins JW. Prospects for treatment of viral hemorrhagic fever with ribavirin - a broad spectrum antiviral drug. Rev Infect Dis 1989; 11(Suppl 4):S750-61.
18. Huggins JW, Hslang CM, Cosgriff TM, et al. Prospective double-blind concurrent placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991; 164:1119-27.
19. Chapman LE, Mertz GJ, Peters CJ, et al. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999; 4:211-9.
20. Chapman LE, Ellis BA, Koster FT, et al. Discriminators between hantavirus-infected and -uninfected persons enrolled in a trial of intravenous ribavirin for presumptive hantavirus pulmonary syndrome. Clin Infect Dis 2002; 34:293-303.
21. Mertz GJ, Miedzinski L, Goade D, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004; 39:1307-13.
22. Mc Clung H, Knight V, Gilbert BE, Wilson SZ, Quarles JM, Divine GW. Ribavirin aerosol treatment of influenza B virus infection. JAMA 1983; 249:2671-4.
23. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? CMAJ 2003; 168:1289-93.
24. Hosoya M, Shigeta S, Mori S, et al. High-dose intravenous ribavirin therapy for subacute sclerosing panencephalitis. Antimicrob Agents Chemother 2001; 45:943-5.
25. McJunkin JE, Khan R, de los Reyes EC, et al. Treatment of severe La Crosse encephalitis with intravenous ribavirin following diagnosis by brain biopsy. Pediatrics 1997; 99:261-5.
26. Chowers MY, Lang R, Nassar F, et al. Clinical characteristics of the West Nile fever outbreak, Israel, 2000. Emerg Infect Dis 2001; 7:675-8.
27. ClinicalTrials.gov. Treatment of Japanese encephalitis. Available at: http://clinicaltrials.gov/ct2/show/NCT00216268? termpribavirin+and+japanese+encephalitis&rankp1. Accessed 13 December 2007.
28. Ted case studies: outbreak of Japanese encephalitis (pig virus) in Maylasia. Available at: http://www.american.edu/TED/pigvirus.htm. Accessed 13 December 2007.
29. Chong HT, Tan CT, Karim N, et al. Outbreak of Nipah encephalitis among pig-farm workers in Malaysia in 1998/1999: was there any role for Japanese encephalitis? Neurol J Southeast Asia 2001; 6:129-34.
30. Economy Watch. Economic profile of Uttar Pradesh. Available at: http://www.economywatch.com/stateprofiles/uttarpradesh/profile.htm. Accessed 13 December 2007.
31. Ravi V, Desai A, Balaji M, et al. Development and evaluation of a rapid IgM capture ELISA (JEV-CheX) for the diagnosis of Japanese encephalitis. J Clin Virol 2006; 35:429-34.
32. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975; 1:480-4.
33. Kumar R, Mathur A, Kumar A, Sharma S, Chakrobarty S, Chaturvedi UC. Clinical features and prognostic indicators of Japanese encephalitis in children. Indian J Med Res 1990; 91:321-7.
34. Solomon T, Dung NM, Kneen R, Gainsborough M, Vaughn DW, Khanh VT. Japanese encephalitis. J Neurol Neurosurg Psychiatr 2000; 68:405-15.
35. Hulley SB, Cummings SR. Designing clinical research: an epidemiologic approach. Baltimore: Williams & Wilkins, 1992.
36. Jacobson J, Hills SL, Winkler JL, et al. Evaluation of three immunoglobulin M antibody capture enzyme-linked immunosorbent assays for diagnosis of Japanese encephalitis. Am J Trop Med Hyg 2007; 77:164-8.
37. Wietzke-Braun P, Meier V, Braun F, Ramadori G. Combination of "lowdose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected nonresponders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol 2001; 7:222-7.
38. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, Connor J. Safety, tolerance and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 1993; 37:532-9.